Faculty Profile
Michael Huber, MMS, PA-C
Associate Professor
Academic Coordinator
Email: mhuber@pco.edu
B.S., Cornell University
B.S., Hahnemann University
MMS, St. Francis College
Clinical Specialty:
- Internal Medicine/Infectious Disease
Selected Representative Publications:
- 2004 - Present Peer Reviewer
- ADVANCE for Physician Assistants
- 11/04 HIV Prevention in MSM (Men having sex with Men)
- 9/04 HIV and Cardiovascular Disease
- 4/06 Co-morbidities and the Human Immunodeficiency Virus
- ADVANCE for Physician Assistants
- 2001 - Video Presentation
- Developed and produced a video presentation to be used for PA faculty development on the subject of “How to develop and facilitate an evidence-based medicine format for clinical seminars”. Clinical cases were developed using this EBM format and presented using students interacting in critical thinking roles as a patient and clinician, facilitated by a faculty member and a student advisory panel.
Professional Affiliations:
- American Academy of Physician Assistants
- Physician Assistant Education Association
- Pennsylvania Society of Physician Assistants
Recognition/Awards:
- 2002 President’s Award Recipient, Student Academy of the American Academy of Physician Assistants
- 2000-2001 Outstanding Faculty Member Service Award, Philadelphia College of Osteopathic Medicine, Physician Assistant Program
Research Activities:
1999 - Research Coordinator
1996 – 1997 Co-InvestigatorA study comparing the absorbent costs of pharmacologic management to successful non-pharmacologic alternative therapy, for the treatment of diabetes mellitus, hyperlipidemia, hypertension, and major depression, to justify alternative therapy costs reimbursement from managed healthcare providers
Project Coordinator: Larry Moses, DC
Sponsor: Mayfair Chiropractic Center
A Phase II, double-blind, placebo controlled study of combination drug anti-retroviral therapy to include a reverse transcriptase inhibitor and a protease inhibitor plus HIV-IT (V) or placebo in HIV-1 infected patients with CD4 count greater than or equal to 100, and HIV-RNA greater than or equal to 1K, but less than or equal to 10 K
Principal Investigator: John L. Turner, MD
Sponsor: Chiron Technologies - Center for Gene Therapy
1996 – 1997 Co-Investigator
A non-comparative, multi-site, open-label, expanded access program of Viracept Ô (Nelfinavir Mesylate) to make treatment available to immunocompromised patients with HIV-1 infection who are unable to take other approved protease inhibitors
Principal Investigator: John L. Turner, MD
Sponsor: Agouron Pharmaceuticals
1996 – 1997 Co-Investigator
An expanded access open-label compassionate use protocol of RemuneÔ in HIV-1 infected patients with CD4 lymphocytes less than 300 cells/mL
Principal Investigator: John L. Turner, MD
Sponsor: Immune Response Corporation
1996 – 1997 Co-Investigator
An expanded access open-label compassionate use protocol of RemuneÔ in HIV-1 infected patients with CD4 T-lymphocytes greater than 550 cells/mL
Principal Investigator: John L. Turner, MD
Sponsor: Immune Response Corporation
1996 – 1997 Co-Investigator
A multicenter, double-blind, phase III adjuvant controlled study of the effect of 10 units of HIV-1 Immunogen, and IFA alone every three months of AIDS free survival in subjects with HIV-1 infection and CD4 T-lymphocytes between 300 and 549 cells/mL regardless of concomitant HIV therapy
Principal Investigator: John L. Turner, MD
Sponsor: Immune Response Corporation
1995 - 1996 Co-Investigator
A double-blind, placebo controlled study TimunoxÔ (Thymopentin) in asymptomatic HIV-1 infected patients receiving either monotherapy (AZT, ddI, d4T or 3TC) or in combination (AZT/ddI or AZT/ddC) or other FDA approved antiretroviral therapy
Principal Investigator: John L. Turner, MD
Sponsor: Immunobiology Research Institute
(0607)